Skip to main content
. 2021 Aug 2;12(4):1652–1661. doi: 10.1016/j.apsb.2021.07.026

Figure 4.

Figure 4

EKL1C effectively inhibits authentic SARS-CoV-2 and HCoV-OC43 infection in vitro and in vivo. (A) EKL1C inhibited authentic SARS-CoV-2 infection in Vero E6 cells in a dose-dependent manner. Data are presented as mean ± SD (n = 3). (B) EKL1C inhibited authentic HCoV-OC43 infection in RD cells in a dose-dependent manner. Data are presented as mean ± SD (n = 3). (C) Reduction of SARS-CoV-2 titer in the lungs of hACE2-Tg mice in the EKL1C pre- and post-treatment groups, compared with the non-treatment control group. ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001. (D) Reduction of HCoV-OC43 titer in the lungs of newborn mice in the EKL1C pre- and post-treatment groups, compared with the non-treatment control group. ∗∗P < 0.01.